Latest Leadership News

Australian Vanadium Limited (AVL) reports strong progress on its integrated vanadium project, moving closer to final feasibility and advancing its utility-scale battery storage system, Project Lumina.

MONEYME has exceeded its FY25 operating cash profit expectations by 20%, driven by robust loan book expansion and improved credit quality, while gearing up for a major credit card launch.

Livium Ltd reported a modest net profit in its battery recycling division for Q4 FY25, while securing significant new contracts and progressing lithium extraction technology development.

American Rare Earths Limited reports strong progress at its Halleck Creek Rare Earths Project, highlighted by exceptional sampling results, key permitting milestones, and a $15 million equity raise to fund development.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

GBM Resources has raised $13 million through a two-tranche placement, repaid $6.2 million in convertible debt, and completed a significant board restructure to accelerate exploration at its Drummond Basin gold projects.

EverGreen Lithium Limited has acquired the Leonora Goldfields Project, adding a JORC-compliant inferred gold resource of 63,000 ounces and setting the stage for a targeted drilling campaign to expand and upgrade this resource.

Helios Energy has made significant strides in transitioning from exploration to production at its Presidio Project in Texas, supported by a $2.6 million capital raise and strategic U.S. hires. Early oil recovery and positive engagement with partners underscore its growing momentum.

FlexiRoam Limited has achieved profitability in Q4 FY25, marking a significant turnaround with a positive EBITDA and net profit. Founder Jefrey Ong is appointed permanent CEO to steer the company’s next growth phase.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.

Cosmo Metals has raised $2 million through a strategic placement to fast-track exploration at its promising NSW gold, antimony, and copper projects, with maiden drilling set to begin this quarter.